190 related articles for article (PubMed ID: 29951943)
1. RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
Hellweg R; Mooneyham A; Chang Z; Shetty M; Emmings E; Iizuka Y; Clark C; Starr T; Abrahante JH; Schütz F; Konecny G; Argenta P; Bazzaro M
Horm Cancer; 2018 Oct; 9(5):326-337. PubMed ID: 29951943
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis.
Rodrigues da Cunha Colombo Bonadio R; Gondim Meira Velame Azevedo R; Harada G; Cabral Severino da Costa S; Costa Miranda V; de Freitas D; Abdo Filho E; Alves de Oliveira Ferreira P; Gabrielli F; Del Pilar Estevez Diz M
J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241227
[TBL] [Abstract][Full Text] [Related]
3. A Cell-Based Method for Identification of Chemotherapy Resistance Cancer Genes.
Hellweg R; Mooneyham A; Bazzaro M
Methods Mol Biol; 2019; 1907():83-90. PubMed ID: 30542992
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin.
Ogane N; Yasuda M; Kameda Y; Yokose T; Kato H; Itoh A; Nishino S; Hashimoto Y; Kamoshida S
Biomed Res; 2013 Jun; 34(3):143-51. PubMed ID: 23782748
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of postoperative radiotherapy combined with taxol+carboplatin chemotherapy regimens in the treatment of high-risk early-stage endometrial cancer.
Kang T; Liu N; Sun X; Liu M
J BUON; 2021; 26(2):561-568. PubMed ID: 34077006
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
Obata H; Aoki Y; Watanabe M; Matsushita H; Yahata T; Fujita K; Kurata H; Tanaka K
Int J Clin Oncol; 2003 Feb; 8(1):53-5. PubMed ID: 12601544
[TBL] [Abstract][Full Text] [Related]
9. Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma.
Fujiwara K; Egawa-Takata T; Ueda Y; Kimura T; Yoshino K; Fujita M; Miyatake T; Ohta Y; Kamiura S; Enomoto T; Kimura T
Arch Gynecol Obstet; 2012 May; 285(5):1447-53. PubMed ID: 22127553
[TBL] [Abstract][Full Text] [Related]
10. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
[TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer].
Misawa A; Nagao M; Kushimoto T; Yasuda M
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1901-5. PubMed ID: 19011339
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
14. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
Rubinstein M; Shen S; Monk BJ; Tan DSP; Nogueira-Rodrigues A; Aoki D; Sehouli J; Makker V
Gynecol Oncol; 2022 Dec; 167(3):540-546. PubMed ID: 36280455
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
16. Tislelizumab Combined with Carboplatin-Paclitaxel for Treatment of Metastatic or Recurrent Endometrial Cancer: a Retrospective Clinical Study.
Gao FF; Zhang XL; Chen JL; Zhang TT; Sui XC; Tang YD; Liu NF
Clin Lab; 2022 Nov; 68(11):. PubMed ID: 36377989
[TBL] [Abstract][Full Text] [Related]
17. Prolonged remission of endometrial cancer with paclitaxel and carboplatin.
Vasuratna A; Kudelka AP; Edwards CL; Wootipoom V; Verschraegen CF; Charnsangavej C; Kavanagh JJ
Anticancer Drugs; 1998 Mar; 9(3):283-5. PubMed ID: 9625439
[TBL] [Abstract][Full Text] [Related]
18. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
Cassier PA; Navaridas R; Bellina M; Rama N; Ducarouge B; Hernandez-Vargas H; Delord JP; Lengrand J; Paradisi A; Fattet L; Garin G; Gheit H; Dalban C; Pastushenko I; Neves D; Jelin R; Gadot N; Braissand N; Léon S; Degletagne C; Matias-Guiu X; Devouassoux-Shisheboran M; Mery-Lamarche E; Allard J; Zindy E; Decaestecker C; Salmon I; Perol D; Dolcet X; Ray-Coquard I; Blanpain C; Bernet A; Mehlen P
Nature; 2023 Aug; 620(7973):409-416. PubMed ID: 37532934
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
